ADVERTISEMENT
Lenvatinib–Pembrolizumab Shows Potential in Advanced Endometrial Cancer
Combining lenvatinib with pembrolizumab demonstrated promising antitumor activity in patients with advanced endometrial cancer that progressed with systemic therapy, regardless of tumor microsatellite instability (MSI) status (J Clin Oncol. 2020 Mar 13. Epub ahead of print).
“Patients with advanced endometrial carcinoma have limited treatment options,” according to Vicky Makker, MD, Memorial Sloan Kettering Cancer Center, New York, and colleagues, who shared findings from a primary efficacy analysis of patients with advanced endometrial cancer given lenvatinib plus pembrolizumab in an ongoing phase 1b/2 clinical trial.
Patients were given lenvatinib 20 mg once daily plus pembrolizumab 200 mg once every 3 weeks in 3-week cycles.
The main end point of the trial was the 24-week objective response rate (ORR), and secondary efficacy end points included response duration, progression-free survival (PFS), and overall survival (OS).
As of the point of data cutoff, 108 patients were enrolled in the study, and follow-up had lasted for a median of 18.7 months. Ultimately, the ORR among these patients at week 24 was 38.0% (95% CI, 28.8%-47.8%).
Among specific groups of patients with MSI-high tumors (n = 11) and microsatellite-stable tumors (n = 94), the 24-week ORRs were 63.6% (95% CI, 30.8%-89.1%) and 36.2% (95% CI, 26.5%-46.7%), respectively.
Regardless of tumor MSI status, pretreated patients had a median response duration of 21.2 months (95% CI, 7.6 months to not estimable), median PFS of 7.4 months (95% CI, 5.3-8.7 months), and median OS of 16.7 months (15.0 months to not estimable).
“Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status,” Dr Makker and colleagues concluded.—Hina M. Porcelli
